Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Bedfont Scientific Ltd. and NewMed Ltd. Proudly Raise Over £28,000 in Funds for Heart of Kent Hospice August 6, 2024 Researchers seek to revolutionize rectal cancer treatment with AI September 19, 2024 WHO publishes report introducing updated terminology for airborne pathogens April 22, 2024
Bedfont Scientific Ltd. and NewMed Ltd. Proudly Raise Over £28,000 in Funds for Heart of Kent Hospice August 6, 2024